Janssen licenses DART molecule from MacroGenics
Johnson & Johnson group Janssen has signed a deal with US biopharma MacroGenics for a license to its preclinical bispecific molecule MGD015.
Read More
Tag: MacroGenics
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
